Wedbush Securities’s Elevance Health ELV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$920K Buy
2,379
+47
+2% +$17.4K 0.02% 511
2026
Q1
$683K Buy
2,332
+107
+5% +$35.2K 0.02% 583
2025
Q4
$780K Sell
2,225
-69
-3% -$23.3K 0.02% 526
2025
Q3
$741K Sell
2,294
-173
-7% -$53.8K 0.02% 526
2025
Q2
$960K Sell
2,467
-153
-6% -$61.5K 0.03% 425
2025
Q1
$1.14M Buy
2,620
+8
+0.3% +$3.21K 0.04% 356
2024
Q4
$963K Sell
2,612
-384
-13% -$161K 0.03% 387
2024
Q3
$1.56M Sell
2,996
-835
-22% -$446K 0.06% 243
2024
Q2
$2.08M Sell
3,831
-22
-0.6% -$11.6K 0.07% 189
2024
Q1
$2M Buy
3,853
+573
+17% +$285K 0.07% 209
2023
Q4
$1.55M Sell
3,280
-114
-3% -$52.7K 0.07% 213
2023
Q3
$1.48M Sell
3,394
-175
-5% -$79.4K 0.07% 205
2023
Q2
$1.59M Buy
3,569
+151
+4% +$69.7K 0.08% 201
2023
Q1
$1.57M Sell
3,418
-115
-3% -$54.7K 0.08% 198
2022
Q4
$1.81M Sell
3,533
-498
-12% -$253K 0.1% 166
2022
Q3
$1.83M Buy
4,031
+1,469
+57% +$703K 0.1% 154
2022
Q2
$1.24M Buy
2,562
+14
+0.5% +$6.93K 0.07% 244
2022
Q1
$1.25M Sell
2,548
-379
-13% -$173K 0.06% 285
2021
Q4
$1.36M Sell
2,927
-606
-17% -$255K 0.06% 284
2021
Q3
$1.32M Sell
3,533
-108
-3% -$41K 0.06% 289
2021
Q2
$1.39M Buy
3,641
+83
+2% +$31.7K 0.07% 276
2021
Q1
$1.28M Buy
+3,558
New +$1.14M 0.07% 267
2020
Q4
Sell
-3,230
Closed -$867K 902
2020
Q3
$867K Sell
3,230
-69
-2% -$18.6K 0.08% 247
2020
Q2
$867K Buy
3,299
+466
+16% +$124K 0.08% 250
2020
Q1
$643K Buy
2,833
+327
+13% +$89.1K 0.08% 287
2019
Q4
$757K Buy
2,506
+277
+12% +$76.2K 0.07% 332
2019
Q3
$535K Buy
2,229
+119
+6% +$32.6K 0.05% 420
2019
Q2
$595K Buy
2,110
+285
+16% +$77.9K 0.06% 367
2019
Q1
$524K Sell
1,825
-36
-2% -$10.4K 0.06% 390
2018
Q4
$489K Sell
1,861
-137
-7% -$37.7K 0.06% 360
2018
Q3
$548K Buy
1,998
+167
+9% +$43.4K 0.06% 364
2018
Q2
$436K Buy
1,831
+652
+55% +$151K 0.05% 419
2018
Q1
$259K Buy
+1,179
New +$277K 0.03% 585

Other funds holding ELV

Wedbush Securities's ELV Position: Q2 2026 in Review

Wedbush Securities increased its Elevance Health (ELV) stake by 2% in Q2 2026, buying an estimated $17.4K and bringing the position to 2,379 shares worth $920K. The position accounts for 0.02% of the portfolio, ranked #511.

Wedbush Securities first reported a position in ELV in Q1 2018 and has held it in 33 quarters since. The position peaked at $2.08M in Q2 2024. 1,601 funds tracked by Wall St. Rank hold ELV as of Q2 2026.

  • Wedbush Securities held 2,379 shares of Elevance Health worth $920K as of Q2 2026.
  • Wedbush Securities bought 47 Elevance Health shares in Q2 2026, an estimated $17.4K.
  • Elevance Health made up 0.02% of Wedbush Securities's portfolio in Q2 2026, its #511 holding.
  • Wedbush Securities first reported a position in Elevance Health in Q1 2018 and has held it in 33 quarters since.
  • Wedbush Securities's Elevance Health position peaked at $2.08M in Q2 2024.
  • 1,601 funds tracked by Wall St. Rank held Elevance Health as of Q2 2026.

Based on Wedbush Securities's 13F filing for Q2 2026, filed 28 Jul 2026.